Amyris shares closed down by nearly 90% on Thursday after the company announced that it had commenced voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court for the District of Delaware.
Han Kieftenbeld, CFO of Amyris, stated, "We remain incredibly excited about Amyris' long-term potential and our uniquely talented team's proven ability to deliver on the promise of synthetic biology and continue to make a lasting impact. At the end of this restructuring process, we believe that Amyris will emerge as a financially stronger company with a more focused business model and well-defined path to profitability."
Amyris shares are moving on heavy trading volume with more than 538 million shares traded in the session, far exceeding the stock's 100-day average of 8.412 million shares.
Related News: Why Ouster Stock Is Climbing Higher Today
AMRS Price Action: According to Benzinga Pro, Amyris shares are up by more than 122% at 15 cents at the time of publication.
Image: geralt from Pixabay
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
